October-December 2019| Vol 2| Issue 4
Letter to the Editor
Cancer immunotherapy in the immunosuppressed patients and its relevance to clinical practice
A recent editorial by Hajjar concisely highlighted the key challenges of cancer immunotherapy in immunocompromised patients. We wish to expand on those emerging issues and their rel...
Letter to the Editor
In the era of immune checkpoint inhibitor therapy, can we safely expand to patients with immunodeficiency?
We have read with great interest the recent issue of the Journal of Immunotherapy and Precision Oncology, which is edited by Dr. Joud Hajjar. It illuminated the area of cancer immunotherapy in immun...
Analysis of Programmed Death-Ligand 1 Expression, Stromal Tumor-Infiltrating Lymphocytes, and Mismatch Repair Deficiency in Invasive Micropapillary Carcinoma of the Breast
Introduction: Invasive micropapillary carcinoma (IMPC) of the breast is a rare and aggressive subtype of invasive ductal carcinomas, associated with poor prognosis and without a well-establis...
Haplotype Analysis of the T-Cell Receptor Beta (TCRB) Locus by Long-amplicon TCRB Repertoire Sequencing
Background: Polymorphism within the human T-cell receptor beta variable (TRBV) gene has been proposed as a risk factor for autoimmune disease and immune-related adverse events (IRAEs) during ...
View All Articles in the Current Issue
Review of immunogenomics and the role of tumor mutational burden as a biomarker for immunotherapy response
Immune checkpoint inhibitors benefit a proportion of patients with cancer, but not all patients nor all histologies will respond to immunotherapy. Therefore, predictive biomarkers are needed. In thi...
Journal of Immunotherapy and Precision Oncology, a publication of Global Academy for Health Sciences, is a peer-reviewed print + online Quarterly journal.
Features of Manuscript Management System
CALL FOR PAPERS
- Online submission
- Wider visibility through open access
- Higher impact
- Prompt review
Special issue 2019
Abstracting and Indexing Information
The journal is registered with the following abstracting partners:
Baidu Scholar, CNKI (China National Knowledge Infrastructure), EBSCO Publishing's Electronic Databases, Ex Libris – Primo Central, Google Scholar, Hinari, Infotrieve, Netherlands ISSN center , ProQuest, TdNet, Wanfang Data